LOG IN
SIGN UP
MARKET
ATNM
ATNM
Actinium Pharmac
AMEX
Real-time Quotes | Nasdaq Last Sale
5.63
+0.13
+2.36%
After Hours: 5.63 0 0.00% 19:13 05/27 EDT
OPEN
5.50
PREV CLOSE
5.50
HIGH
5.63
LOW
5.32
VOLUME
219.93K
TURNOVER
0
52 WEEK HIGH
10.30
52 WEEK LOW
4.410
MARKET CAP
133.91M
P/E (TTM)
-4.9360
1D
5D
1M
3M
1Y
5Y
Has Alkermes (ALKS) Outpaced Other Medical Stocks This Year?
Here is how Alkermes (ALKS) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.
Zacks · 05/19 13:40
BRIEF-Actinium Presents Data From Phase 3 SIERRA Trial
reuters.com · 04/25 11:37
Actinium Pharmaceuticals, Inc. Announces 82% of Control Arm Patients Did Not Receive a Bone Marrow Transplant by Conventional Means but 100% of Patients who Received Iomab-B, Including Crossover Patients, in the Phase 3 SIERRA Trial Successfully Engrafted at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for patients with unmet needs today highlighted data from full patient enrollment in the pivotal Phase 3 SIERRA trial of I...
PR Newswire · 04/25 11:30
BRIEF-Actinium Pharmaceuticals Inc To Highlight IOMAB-B Pivotal Phase 3 Sierra Trial Data At The Transplantation & Cellular Therapy Tandem Meetings Of Astct And Cibmtr
reuters.com · 04/19 11:33
Actinium Pharmaceuticals, Inc. to Highlight Iomab-B Pivotal Phase 3 SIERRA Trial Data at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies for patients with unmet needs today highlighted its activity at the upcoming Transplantation & Cellular Therapy (TCT) Tand...
PR Newswire · 04/19 11:30
Actinium (ATNM) Up on Commercialization Deal With Immedica
Actinium (ATNM) out-licenses exclusive rights to Iomab-B, an antibody radiation conjugate for facilitating bone-marrow transplant, to Immedica in Europe, the Middle East and North African countries.
Zacks · 04/13 19:36
Actinium maintained at outperform at William Blair following Immedica Pharma deal
William Blair is maintaining Actinium Pharmaceuticals at outperform after the company's license and supply agreement with Immedica Pharma AB for Iomab-B. That agreement, announced Tuesday, provides Actinium (NYSE:ATNM) with a
Seekingalpha · 04/13 19:34
--Alliance Global Adjusts Price Target on Actinium Pharmaceuticals to $25 From $20, Maintains Buy Rating
MT Newswires · 04/13 05:40
No Data
Learn about the latest financial forecast of ATNM. Analyze the recent business situations of Actinium Pharmac through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 5 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
20.00%Strong Buy
80.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average ATNM stock price target is 29.25 with a high estimate of 45.00 and a low estimate of 22.00.
Current 5.63
EPS
Actual
Estimate
-0.080.210.490.78
Institutional Holdings
Institutions: 42
Institutional Holdings: 23.40M
% Owned: 98.37%
Shares Outstanding: 23.78M
TypeInstitutionsShares
Increased
10
5.54M
New
5
10.91M
Decreased
6
1.59M
Sold Out
5
306.41K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Chairman/Chief Executive Officer/Director
Sandesh Seth
Chief Financial Officer/Secretary
Steve O'Loughlin
Other
Avinash Desai
Other
Arun Swaminathan
Lead Director/Independent Director
C. David Nicholson
Independent Director
Jeffrey Chell
Independent Director
Ajit Shetty
Independent Director
Richard Steinhart
No Data
No Data
About ATNM
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on Antibody Radiation-Conjugates (ARCs), which combine the targeting ability of antibodies with the cell-killing ability of radiation. Its clinical programs are focused on two primary areas: targeted conditioning prior to bone marrow transplant, adoptive cell or gene therapies and therapeutics, in combination with other therapeutic modalities. Its clinical pipeline is focused on ARCs targeting the antigens CD45 and CD33, both of which are expressed in multiple hematologic cancers. Its lead CD45-targeted conditioning product candidate, Iomab-B, via the monoclonal antibody BC8, targets CD45, an antigen expressed on leukemia and lymphoma cancer cells, B cells and stem cells. Its CD33 program is evaluating the clinical utility of Actimab-A, an ARC consisting of the anti-CD33 mAb lintuzumab linked to the potent alpha-emitting radioisotope Actinium-225 (Ac-225).
Webull offers kinds of Actinium Pharmaceuticals Inc stock information, including AMEX:ATNM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATNM stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading ATNM stock methods without spending real money on the virtual paper trading platform.